1.	Efficacy and Safety of a Donor Lymphocyte Preparation Depleted of Functional Host Alloreactive T-cells (ATIR) in Patients Undergoing a Peripheral Blood Stem Cell Transplant From a Related, Haploidentical Donor Phase: Phase III, Phase II Type: Supportive care Status: Temporarily closed Age: 18 to 65 Sponsor: Pharmaceutical / Industry Protocol IDs: CR-AIR-004, EudraCT no. 2008-008198-73, NCT00967343
2.	Phase III Randomized Controlled Trial of Allogeneic Cytotoxic T-Cell Immunotherapy Following Reduction of Immunosuppression in Solid Organ Transplant Patients With Epstein-Barr Virus-Associated B-Cell Lymphoproliferative Disease Phase: Phase III Type: Treatment Status: Closed Age: Any age Sponsor: Other Protocol IDs: CRUK-EBV-CTL, LCMV-CTL, EU-20057, NCT00033475
3.	Phase I/II Study of HLA-Matched Peripheral Blood Mobilized Hematopoietic Progenitor Cell Transplantation Followed by Allogeneic T-cell Infusion as Adoptive Immunotherapy in Patients With Metastatic Melanoma Phase: Phase II, Phase I Type: Treatment Status: Closed Age: 18 to 60 Sponsor: NHLBI Protocol IDs: NHLBI-98-H-0006, NCT00003552
4.	Biological Therapy in Treating Patients With Advanced Myelodysplastic Syndrome, Acute or Chronic Myeloid Leukemia, or Acute Lymphoblastic Leukemia Who Are Undergoing Stem Cell Transplantation Phase: Phase II, Phase I Type: Biomarker/Laboratory analysis, Treatment Status: Closed Age: 75 and under Sponsor: NCI, Other Protocol IDs: 1655.00, NCI-2009-01471, P01CA018029, FHCRC-1655.00, 5430, NCT00052520
5.	Donor Lymphocyte Infusion in Treating Patients With Persistent, Relapsed, or Progressing Cancer After Donor Hematopoietic Cell Transplant Phase: Phase II, Phase I Type: Treatment Status: Closed Age: Any age Sponsor: NCI, Other Protocol IDs: 1803.00, NCI-2010-00163, P01CA078902, FHCRC-1803.00, 5606, NCT00068718
6.	Phase I/II Pilot Study of a Reduced-Intensity Conditioning Regimen Comprising Alemtuzumab, Fludarabine, and Melphalan With or Without Cyclosporine, Mycophenolate Mofetil, and Low-Dose Total Body Radiotherapy Followed By Haplotype-Mismatched, KIR Class I Epitope-Mismatched CD34-Positive Allogeneic Peripheral Blood Stem Cell Transplantation in Patients With Relapsed, Refractory, or Poor-Risk Hematological Malignancies Phase: Phase II, Phase I Type: Treatment Status: Completed Age: 18 to 60 Sponsor: NCI Protocol IDs: CALGB-100102, NCT00085449
7.	Phase I/II Study of Adoptive Immunotherapy Comprising HyTK-Transduced Allogeneic Polyclonal T Cells in Patients With Relapsed Chronic Myelogenous Leukemia After Prior Allogeneic Hematopoietic Stem Cell Transplantation Phase: Phase II, Phase I Type: Treatment Status: Closed Age: 18 and over Sponsor: Other Protocol IDs: FHCRC-1135.00
8.	Donor Natural Killer Cell Therapy and Aldesleukin in Treating Patients With High Risk Acute Myeloid Leukemia Undergoing Donor Stem Cell Transplant Phase: Phase II, Phase I Type: Treatment Status: Closed Age: 18 to 70 Sponsor: Other Protocol IDs: 2004LS042, UMN-MT2003-23, UMN-IRB-0405M60481, UMN-2004LS042, NCT00303667
9.	Phase I/II Pilot Study of Induction Therapy Comprising Fludarabine and Cyclophosphamide Followed By Allogeneic Stem Cell Transplantation in Patients With High-Risk B-Cell Chronic Lymphocytic Leukemia or Waldenstrom's Macroglobulinemia Phase: Phase II, Phase I Type: Treatment Status: Closed Age: 18 to 65 Sponsor: Other, Pharmaceutical / Industry Protocol IDs: GCLLSG-CLL3X, EU-20554, MEDAC-FLUD.10/CLL, NCT00281983
10.	Fludarabine and PK-Directed Busulfan With or Without ATG Followed By Donor Peripheral Stem Cell Transplant in Treating Patients With Hematologic Cancer or Other Diseases Phase: Phase II, Phase I Type: Treatment Status: Closed Age: 18 to 55 Sponsor: NCI, Other Protocol IDs: LCCC 0510, P30CA016086, CDR0000550145, UNC-LCCC-0510, NCT00448357
11.	Study of Bioengineered Allogeneic Immune Cells (AlloStim) Not Requiring HLA Donor Match Alternative to Allogeneic Transplant for Blood Cancers Phase: Phase II, Phase I Type: Treatment Status: Closed Age: 18 and over Sponsor: Pharmaceutical / Industry Protocol IDs: ITL-001-HM, NCT00861965
12.	Chemotherapy Followed by Donor White Blood Cells Plus Interleukin-2 in Treating Patients With Acute Myeloid or Lymphocytic Leukemia Phase: Phase II, Phase I Type: Treatment Status: Completed Age: Not specified Sponsor: NCI, Other Protocol IDs: 1380.00, FHCRC-1380.00, NCI-H00-0057, CDR0000067777, NCT00005802
13.	Low-Dose Total-Body Irradiation and Fludarabine Phosphate Followed By Donor Peripheral Blood Stem Cell Transplant in Treating Patients With Stage IV Kidney Cancer Phase: Phase II, Phase I Type: Treatment Status: Closed Age: Under 75 Sponsor: NCI, Other Protocol IDs: 1495.00, NCI-2012-00581, FHCRC-1495.00, NCI-G00-1790, NCT00005851
14.	Chemotherapy, Radiation Therapy, Peripheral Stem Cell Transplantation, and Immunosuppressive Therapy in Treating Patients With Cancer Phase: Phase II, Phase I Type: Treatment Status: Completed Age: Under 75 Sponsor: NCI, Other Protocol IDs: 1533.00, FHCRC-1533.00, NCI-H00-0062, CDR0000068184, NCT00006251
15.	Combination Chemotherapy and Total-Body Irradiation Followed by Peripheral Stem Cell or Bone Marrow Transplantation in Treating Patients With Acute Lymphoblastic Leukemia Phase: Phase II, Phase I Type: Treatment Status: Completed Age: 75 and under Sponsor: NCI, Other Protocol IDs: 1586.00, FHCRC-1586.00, NCI-H01-0080, CDR0000069042, NCT00027547
16.	Total-Body Irradiation and Fludarabine Phosphate Followed by Donor Peripheral Blood Stem Cell Transplant in Treating Patients With Hematologic Malignancies or Kidney Cancer Phase: Phase II, Phase I Type: Treatment Status: Closed Age: Any age Sponsor: NCI, Other Protocol IDs: 1641.00, NCI-2012-00591, P01CA018029, P01HL036444, FHCRC-1641.00, NCI-H01-0081, NCT00027820
17.	Reduced-Intensity Conditioning Followed By Donor Peripheral Blood Stem Cell Transplant in Treating Patients With Multiple Myeloma Phase: Phase II, Phase I Type: Treatment Status: Closed Age: 18 to 70 Sponsor: NCI, Other Protocol IDs: 1743.00, NCI-2011-00386, P01CA078902, FHCRC-1743.00, 5476, NCT00054353
18.	Donor White Blood Cell Infusions and Interleukin-2 in Treating Patients Who Are Undergoing an Autologous Stem Cell Transplant for Relapsed Advanced Lymphoid Cancer Phase: Phase II, Phase I Type: Treatment Status: Completed Age: 18 to 69 Sponsor: Other Protocol IDs: 1838.00, FHCRC-1838.00, CDR0000430694, NCT00248430
19.	Phase II Study of Salvage Cellular Immunotherapy With Donor Lymphocyte Infusions in Patients With Recurrent Multiple Myeloma After Allogeneic Bone Marrow Transplantation from an HLA-Matched Sibling Donor Phase: Phase II Type: Treatment Status: Completed Age: 18 and over Sponsor: NCI Protocol IDs: ECOG-E1A97, E1A97, NCT00003153
20.	Phase II Study of Nonmyeloblative Allogeneic Peripheral Blood Stem Cell Transplantation and Donor Lymphocyte Infusions in Patients With Refractory Metastatic Solid Tumors Phase: Phase II Type: Treatment Status: Closed Age: 10 to 80 Sponsor: NHLBI Protocol IDs: NHLBI-99-H-0064, NCT00003839
21.	Chemotherapy Plus Peripheral Stem Cell Transplantation in Treating Patients With Melanoma or Metastatic Kidney Cancer Phase: Phase II Type: Treatment Status: Closed Age: 18 to 65 Sponsor: NCI, Other Protocol IDs: CDR0000067365, UCCRC-9672, UCCRC-CTRC-9866, NCI-G99-1612, NCT00004135
22.	Phase II Study of Low Dose Total Body Irradiation, Followed By Allogeneic Peripheral Blood Stem Cell Transplantation, Followed By Donor Lymphocyte Infusion in Older Patients With Acute Myeloid Leukemia Phase: Phase II Type: Treatment Status: Closed Age: Over 55 to under 75 Sponsor: NCI Protocol IDs: UCHSC-00119, FHCRC-1406.00, NCI-G00-1778, NCT00005801
23.	Phase II Study of T-Cell-Depleted Allogeneic Peripheral Blood Stem Cell Transplantation in Patients With Metastatic Breast Cancer Phase: Phase II Type: Treatment Status: Completed Age: 18 to 70 Sponsor: NCI Protocol IDs: NCI-00-C-0119, NCI-1027, NCT00020176
24.	Fludarabine and Cyclophosphamide Followed by Peripheral Stem Cell Transplant in Treating Patients With Leukemia or Lymphoma Phase: Phase II Type: Treatment Status: Closed Age: Under 70 Sponsor: NCI, Other Protocol IDs: CDR0000068185, U10CA031946, CALGB-109901, NCT00006252
25.	Phase II Study of Nonmyeloablative Conditioning Regimen Followed by HLA Matched Sibling Donor Peripheral Blood Stem Cell Transplantation in Patients With Hematologic Malignancies (Summary Last Modified 01/2002) Phase: Phase II Type: Treatment Status: Closed Age: Over 18 Sponsor: Other Protocol IDs: MSGCC-0012, NCI-V00-1624, NCT00006350